Millennium Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.4M | Buy |
160,000
+124,300
| +348% | +$19.1M | 0.01% | 1382 |
|
|
2025
Q4 | $4.92M | Sell |
35,700
-195,000
| -85% | -$25.5M | ﹤0.01% | 3029 |
|
|
2025
Q3 | $29.6M | Buy |
230,700
+68,000
| +42% | +$8.3M | 0.01% | 1275 |
|
|
2025
Q2 | $19.7M | Buy |
162,700
+60,000
| +58% | +$6.76M | 0.01% | 1586 |
|
|
2025
Q1 | $11.4M | Sell |
102,700
-3,400
| -3% | -$362K | 0.01% | 2049 |
|
|
2024
Q4 | $10.3M | Buy |
106,100
+100,000
| +1,639% | +$10.7M | 0.01% | 2150 |
|
|
2024
Q3 | $702K | Sell |
6,100
-204,600
| -97% | -$23.2M | ﹤0.01% | 4554 |
|
|
2024
Q2 | $22.4M | Sell |
210,700
-40,900
| -16% | -$4.11M | 0.01% | 1394 |
|
|
2024
Q1 | $24.3M | Buy |
251,600
+45,000
| +22% | +$4.61M | 0.01% | 1394 |
|
|
2023
Q4 | $20.9M | Buy |
206,600
+183,800
| +806% | +$17.7M | 0.01% | 1505 |
|
|
2023
Q3 | $2.32M | Sell |
22,800
-694,700
| -97% | -$70.5M | ﹤0.01% | 3412 |
|
|
2023
Q2 | $72.4M | Buy |
717,500
+202,000
| +39% | +$20.2M | 0.04% | 507 |
|
|
2023
Q1 | $47.4M | Sell |
515,500
-59,500
| -10% | -$5.2M | 0.03% | 720 |
|
|
2022
Q4 | $52.2M | Buy |
+575,000
| New | +$48.4M | 0.03% | 722 |
|
|
2022
Q3 | – | Sell |
-400,000
| Closed | -$33.8M | – | 7368 |
|
|
2022
Q2 | $33.8M | Buy |
+400,000
| New | +$35.1M | 0.02% | 880 |
|
|
2021
Q4 | – | Sell |
-250,000
| Closed | -$20.4M | – | 7196 |
|
|
2021
Q3 | $20.4M | Buy |
+250,000
| New | +$22.5M | 0.01% | 1306 |
|
|
2021
Q2 | – | Sell |
-100,000
| Closed | -$8.55M | – | 6917 |
|
|
2021
Q1 | $8.55M | Buy |
+100,000
| New | +$8.97M | 0.01% | 1963 |
|
|
2020
Q4 | – | Sell |
-340,000
| Closed | -$29.6K | – | 5473 |
|
|
2020
Q3 | $29.6K | Buy |
+340,000
| New | +$29.5M | 0.04% | 565 |
|
|
2020
Q1 | – | Sell |
-300,100
| Closed | -$28.4M | – | 4285 |
|
|
2019
Q4 | $28.4M | Buy |
+300,100
| New | +$26.9M | 0.04% | 631 |
|
|
2019
Q3 | – | Sell |
-400,200
| Closed | -$36.5M | – | 4441 |
|
|
2019
Q2 | $36.5M | Buy |
400,200
+167,291
| +72% | +$14.2M | 0.05% | 468 |
|
|
2019
Q1 | $20.1M | Buy |
+232,909
| New | +$18.7M | 0.03% | 797 |
|
|
2018
Q3 | – | Sell |
-334,800
| Closed | -$22.7M | – | 4166 |
|
|
2018
Q2 | $22.7M | Buy |
+334,800
| New | +$23.1M | 0.03% | 781 |
|
|
2014
Q4 | – | Sell |
-4,241
| Closed | -$358K | – | 4178 |
|
|
2014
Q3 | $358K | Sell |
4,241
-558
| -12% | -$45.1K | ﹤0.01% | 2951 |
|
|
2014
Q2 | $389K | Buy |
+4,799
| New | +$377K | ﹤0.01% | 2736 |
|
Other funds holding NVS
Millennium Management's NVS Position: Q1 2026 in Review
Millennium Management sold out of Novartis (NVS) in Q1 2026, closing a stake of 10,579 shares — an estimated $1.62M sold.
Millennium Management first reported a position in NVS in Q2 2013 and held it in 45 quarters. The position peaked at $120M in Q3 2018. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Millennium Management reported no remaining Novartis position as of Q1 2026 after selling out during the quarter.
- Millennium Management sold 10,579 Novartis shares in Q1 2026, an estimated $1.62M.
- Millennium Management first reported a position in Novartis in Q2 2013 and held it in 45 quarters.
- Millennium Management's Novartis position peaked at $120M in Q3 2018.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.